Aptus will follow their Cancer Treatment program with AptaBreast (RTC2019-007227-1) financed by MCIN/AEI /10.13039/501100011033 as well as European Union NextGenerationEU/ PRTR: Preclinical Development of an aptamer for cancer treatment.
AptaBreast project aims to address the preclinical phase (non-regulatory and regulatory) by the aptamer development for breast cancer therapy (Aptus Biotech and FIBio-HRC), as well as to study its potential efficacy in pancreatic cancer treatment (UAM).